"Melphalan" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.
| Descriptor ID |
D008558
|
| MeSH Number(s) |
D02.455.526.728.650.594 D12.125.072.050.685.500
|
| Concept/Terms |
Melphalan- Melphalan
- L-PAM
- Phenylalanine Mustard
- Mustard, Phenylalanine
- 4-(Bis(2-chloroethyl)amino)phenylalanine
|
Below are MeSH descriptors whose meaning is more general than "Melphalan".
Below are MeSH descriptors whose meaning is more specific than "Melphalan".
This graph shows the total number of publications written about "Melphalan" by people in this website by year, and whether "Melphalan" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 2 | 1 | 3 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 3 | 3 |
| 2025 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Melphalan" by people in Profiles.
-
Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation. Nat Genet. 2025 Jul; 57(7):1695-1707.
-
Fludarabine Plus Myeloablative Dose of Busulfan Regimen Was Associated with High Nonrelapse Mortality in Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Lymphoma: A Propensity Score-Matched Comparison Study with Fludarabine Plus High-Dose Melphalan. Transplant Cell Ther. 2025 Jun; 31(6):382.e1-382.e17.
-
Incidence and Risk Factors for Neutropenia After Intra-Arterial Chemotherapy for Retinoblastoma. JAMA Ophthalmol. 2023 12 01; 141(12):1133-1138.
-
Angiographic characteristics and treatment approach in patients undergoing intra-arterial chemotherapy for retinoblastoma. Graefes Arch Clin Exp Ophthalmol. 2024 Apr; 262(4):1321-1328.
-
Growth hormone-releasing hormone receptor antagonist MIA-602 attenuates cardiopulmonary injury induced by BSL-2 rVSV-SARS-CoV-2 in hACE2 mice. Proc Natl Acad Sci U S A. 2023 11 28; 120(48):e2308342120.
-
A multi-institutional feasibility study of intra-arterial chemotherapy in children with retinoblastoma. A Children's Oncology Group study (COG ARET12P1). Pediatr Blood Cancer. 2024 Jan; 71(1):e30718.
-
Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT. Blood Adv. 2023 07 25; 7(14):3725-3734.
-
Improved survival after single-unit cord blood transplantation using fludarabine and melphalan-based reduced-intensity conditioning for malignant lymphoma: impact of melphalan dose and graft-versus-host disease prophylaxis with mycophenolate mofetil. Ann Hematol. 2022 Dec; 101(12):2743-2757.
-
Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma. Bone Marrow Transplant. 2022 04; 57(4):579-585.
-
Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. Transplant Cell Ther. 2021 06; 27(6):490.e1-490.e8.